圣地亚哥的一家生物技术公司以90亿美元的价格出售其普及流感疫苗,这是预防流感方面的一个重大飞跃。 A San Diego biotech sold its universal flu vaccine for $9 billion, a major leap in flu prevention.

一家设在圣地亚哥的加利福尼亚州生物技术创办公司以90亿美元的价格出售其普及流感疫苗,标志着传染病预防工作取得重大突破。 A California biotech startup based in San Diego has sold its universal flu vaccine for $9 billion, marking a major breakthrough in infectious disease prevention. 2024年后期最后敲定的这项协议反映出人们对疫苗防止多种流感菌株的能力越来越有信心,有可能消除每年射击的必要性。 The deal, finalized in late 2024, reflects growing confidence in the vaccine’s ability to protect against multiple flu strains, potentially eliminating the need for annual shots. 该公司以前筹集了少量资金,经过临床试验后取得了迅速的成功,表现出强劲、广度的免疫力。 The company, which had previously raised modest funding, achieved rapid success after clinical trials showed strong, broad-spectrum immunity. 一个全球制药巨头的收购突出表明,对下一代疫苗的投资日益增加。 The acquisition by a global pharmaceutical giant underscores increasing investment in next-generation vaccines.